2015
Enteric‐coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal‐transplant recipients compared with mycophenolate mofetil
Feng J, Zhang L, Zhao P, Bow L, Tian J. Enteric‐coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal‐transplant recipients compared with mycophenolate mofetil. International Journal Of Clinical Practice Supplement 2015, 69: 1-7. PMID: 26176848, DOI: 10.1111/ijcp.12660.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultChinaDose-Response Relationship, DrugEnzyme InhibitorsFemaleFollow-Up StudiesGraft RejectionHumansImmunosuppressive AgentsIncidenceKidney TransplantationMaleMiddle AgedMycophenolic AcidProspective StudiesSurgical Wound InfectionTablets, Enteric-CoatedTacrolimusTransplant RecipientsConceptsAsian renal transplant recipientsRenal transplant recipientsEnteric-coated mycophenolate sodiumEC-MPSMycophenolate sodiumMMF groupIncidence of infectionMycophenolate mofetilSerious infectionsAdverse eventsLower incidenceTherapeutic effectLive donor kidney transplant recipientsInfection rateGastro-intestinal adverse eventsClinical trial registration numberIncidence of biopsyPosttransplant infection ratesTimes of diarrheaKidney transplant recipientsSerum creatinine levelsTRIAL REGISTRATION NUMBEREnteric-coated formulationAcute rejectionRenal transplantation
2001
Use of cryopreserved cadaveric vein allograft for hemodialysis access precludes kidney transplantation because of allosensitization
Benedetto B, Lipkowitz G, Madden R, Kurbanov A, Hull D, Miller M, Bow L. Use of cryopreserved cadaveric vein allograft for hemodialysis access precludes kidney transplantation because of allosensitization. Journal Of Vascular Surgery 2001, 34: 139-142. PMID: 11436087, DOI: 10.1067/mva.2001.114206.Peer-Reviewed Original ResearchConceptsVein allograftsHemodialysis accessPRA valuesControl cohortPRA assaysWaiting listKidney transplantation waiting listPanel-reactive antibodies valuesPotential kidney transplant recipientsUniversity-affiliated medical centerMajor histocompatibility complex IKidney transplant recipientsHistory of transfusionTransplant waiting listTransplantation waiting listMean PRANonimmunosuppressed individualsHemodialysis populationKidney transplantationPrior transplantationTransplant recipientsConsecutive patientsProsthetic graftsAntibody valuesKidney failure
2000
Response to “A Novel United Network for Organ Sharing Region Kidney Allocation Plan Improves Transplant Access for Minority Candidates”
Hull D, Bow L, Mather J. Response to “A Novel United Network for Organ Sharing Region Kidney Allocation Plan Improves Transplant Access for Minority Candidates”. Transplantation 2000, 70: 1113. PMID: 11045655, DOI: 10.1097/00007890-200010150-00024.Peer-Reviewed Original ResearchModulation of efficacies and pharmacokinetics of antibiotics by granulocyte colony-stimulating factor in neutropenic mice with multidrug-resistant Enterococcus faecalis infection
Onyeji C, Nicolau D, Nightingale C, Bow L. Modulation of efficacies and pharmacokinetics of antibiotics by granulocyte colony-stimulating factor in neutropenic mice with multidrug-resistant Enterococcus faecalis infection. Journal Of Antimicrobial Chemotherapy 2000, 46: 429-436. PMID: 10980170, DOI: 10.1093/jac/46.3.429.Peer-Reviewed Original ResearchConceptsGranulocyte colony-stimulating factorG-CSFColony-stimulating factorInfected animalsNeutropenic miceFaecalis infectionDisposition of vancomycinNon-neutropenic animalsEnterococcus faecalis infectionPharmacokinetics of antibioticsInduction of neutropeniaConcentration-time curveEfficacy of gentamicinDose-dependent increaseE. faecalis infectionNeutropenic patientsPharmacokinetic interactionsDosing regimensSame infectionPlasma clearanceUseful adjunctGentamicinInfectionVancomycinMice
1999
A new allocation plan for renal transplantation
Delmonico F, Harmon W, Lorber M, Goguen J, Mah H, Himmelfarb J, Lipkowitz G, Valliere S, Bow L, Milford E, Rohrer R. A new allocation plan for renal transplantation. Transplantation Proceedings 1999, 31: 358-359. PMID: 10083141, DOI: 10.1016/s0041-1345(98)01660-1.Peer-Reviewed Original ResearchInterferon-γ effects on activities of gentamicin and vancomycin against Enterococcus faecalis resistant to the drugs: an in vitro study with human neutrophils
Onyeji C, Nicolau D, Nightingale C, Bow L. Interferon-γ effects on activities of gentamicin and vancomycin against Enterococcus faecalis resistant to the drugs: an in vitro study with human neutrophils. International Journal Of Antimicrobial Agents 1999, 11: 31-37. PMID: 10075275, DOI: 10.1016/s0924-8579(98)00085-5.Peer-Reviewed Original ResearchConceptsIFN-gammaHuman neutrophilsMajor therapeutic challengeMultidrug-resistant E. faecalisAnti-enterococcal activityEffective antimicrobial therapyMultidrug-resistant enterococciActivity of gentamicinPotential underlying mechanismsEnterococcus faecalisTherapeutic troughMaximal growth inhibitionTherapeutic challengeSerum troughReactive oxygen intermediatesAntimicrobial therapyUseful adjunctClinical isolatesActivated secretionNeutrophilsPeak levelsGentamicinVancomycinPeak concentrationE. faecalisA NEW ALLOCATION PLAN FOR RENAL TRANSPLANTATION1
Delmonico F, Harmon W, Lorber M, Goguen J, Mah H, Himmelfarb J, Lipkowitz G, Valliere S, Bow L, Milford E, Rohrer R. A NEW ALLOCATION PLAN FOR RENAL TRANSPLANTATION1. Transplantation 1999, 67: 303-309. PMID: 10075599, DOI: 10.1097/00007890-199901270-00021.Peer-Reviewed Original ResearchConceptsDR mismatchesTransplant centersDonor availabilityPanel reactive antibodyPercentage of patientsMultiple transplant centersNumber of patientsAllograft allocationRENAL TRANSPLANTATION1Renal transplantationNegative patientsPediatric patientsHLA matchingUnited NetworkCadaver donorsDonor hospitalPatientsInterval changesKidneyTotal numberHLA pointsTime waitingTRANSPLANTATION1TransplantationHLA
1997
In vitro reduction of endotoxin concentrations with the 5S fragment of immunoglobulin G
Xuan D, Nicolau D, Tessier P, Bow L, Quintiliani R, Nightingale C. In vitro reduction of endotoxin concentrations with the 5S fragment of immunoglobulin G. Antimicrobial Agents And Chemotherapy 1997, 41: 1512-1516. PMID: 9210676, PMCID: PMC163950, DOI: 10.1128/aac.41.7.1512.Peer-Reviewed Original ResearchConceptsNegative sepsisAntiendotoxin activityEndotoxin releaseTreatment of sepsisEndotoxin concentrationsTime-kill studiesDose-effect relationRapid bactericidal effectBacterial colony countsColony countsAdjuvant therapyMean reductionSepsisE. coli CFUCFU/Further studiesMajor targetTherapyVitro reductionCefotaximeConcentration curveImmunoglobulin G.Bactericidal effectBactericidal actionBacterial proliferation
1996
Organ transplantation at the Hartford Transplant Center.
Schweizer R, Bartus S, Hull D, Perdrizet G, Swanson M, Low H, Gallagher R, Dougherty J, Rosson R, Hyams J, D'Avella J, Rasoulpour M, Sullivan P, Bow L. Organ transplantation at the Hartford Transplant Center. Connecticut Medicine 1996, 60: 387-93. PMID: 8758656.Peer-Reviewed Original ResearchConceptsTransplant centersActuarial graft survivalRecipients of kidneysMost transplant centersTwo-year survivalHealth care communityTriple immunosuppressionGraft survivalKidney transplantationLiver transplantRelated donorsCadaveric kidneysHigh success rateDonor organsOrgan transplantationOrgan transplantsPancreas patientsKidneySuccess rateSurvivalTransplantationTransplantNational averageHeartImmunosuppression
1995
Activities of Clarithromycin, Azithromycin, and Ofioxacin in Combination with Liposomal or Unencapsulated Granulocyte-Macrophage Colony-Stimulating Factor against Intramacrophage Mycobacterium avium-Mycobacterium intracellulare
Onyeji C, Nightingale C, Tessier P, Nicolau D, Bow L. Activities of Clarithromycin, Azithromycin, and Ofioxacin in Combination with Liposomal or Unencapsulated Granulocyte-Macrophage Colony-Stimulating Factor against Intramacrophage Mycobacterium avium-Mycobacterium intracellulare. The Journal Of Infectious Diseases 1995, 172: 810-816. PMID: 7658075, DOI: 10.1093/infdis/172.3.810.Peer-Reviewed Original ResearchConceptsMycobacterium avium-Mycobacterium intracellulareGranulocyte-macrophage colony-stimulating factorColony-stimulating factorGM-CSFHuman macrophage infection modelMaximal killing effectTherapeutic peak concentrationsTherapeutic trough concentrationsActivity of clarithromycinEffects of ofloxacinMacrophage infection modelMAI infectionTrough concentrationsSerum troughUseful adjunctClarithromycinAzithromycinInfection modelPeak levelsSignificant augmentationKilling effectPeak concentrationOfloxacinAntimycobacterial activityIntracellulareEnhanced intracoronary thrombolysis with urokinase using a novel, local drug delivery system. In vitro, in vivo, and clinical studies.
Mitchel J, Fram D, Palme D, Foster R, Hirst J, Azrin M, Bow L, Eldin A, Waters D, McKay R. Enhanced intracoronary thrombolysis with urokinase using a novel, local drug delivery system. In vitro, in vivo, and clinical studies. Circulation 1995, 91: 785-93. PMID: 7828307, DOI: 10.1161/01.cir.91.3.785.Peer-Reviewed Original ResearchConceptsDispatch catheterLocal infusionEnd-hole catheterU urokinaseCatheter infusionIntracoronary thrombusAngioplasty siteUrokinase administrationLocal drug delivery systemIntracoronary thrombolysisUrokinase infusionBalloon angioplastySystemic bolusIntramural depositionNew local drug delivery systemDistal coronary flowLocal urokinase deliveryLocal urokinase infusionThrombus-containing stenosesConventional balloon angioplastyInfusion of urokinaseInfusion of salinePorcine coronary arteriesSystemic fibrinolytic stateCardiac catheterization laboratory
1994
Inhibition of platelet deposition and lysis of intracoronary thrombus during balloon angioplasty using urokinase-coated hydrogel balloons.
Mitchel J, Azrin M, Fram D, Hong M, Wong S, Barry J, Bow L, Curley T, Kiernan F, Waters D. Inhibition of platelet deposition and lysis of intracoronary thrombus during balloon angioplasty using urokinase-coated hydrogel balloons. Circulation 1994, 90: 1979-1988. PMID: 7923688, DOI: 10.1161/01.cir.90.4.1979.Peer-Reviewed Original ResearchConceptsLocal urokinase deliveryVivo balloon angioplastyIntracoronary thrombusBalloon angioplastyPlatelet depositionThrombotic closureDistal embolizationAngioplasty siteAbrupt closureArterial wallHydrogel balloonContralateral control arteriesContralateral control vesselsIntramural drug deliveryVivo studiesConventional balloon angioplastyNew Zealand rabbitsU urokinaseConventional angioplastyBalloon dilatationClinical efficacyReflow phenomenonIliac arteryBlood exposureControl arteries
1993
Causes of late graft failure in cadaveric renal transplantation.
Bergmann L, Roper L, Bow L, Hull D, Bartus S, Schweizer R. Causes of late graft failure in cadaveric renal transplantation. Transplantation Proceedings 1993, 25: 1340-1. PMID: 8442136.Peer-Reviewed Original Research
1992
Late graft loss in cadaveric renal transplantation.
Bergmann L, Roper L, Bow L, Hull D, Bartus S, Schweizer R. Late graft loss in cadaveric renal transplantation. Transplantation Proceedings 1992, 24: 2718-9. PMID: 1465913.Peer-Reviewed Original Research
1989
Transplantation of cadaver kidneys from pediatric and older donors.
Bow L, Roper L, Bartus S, Hull D, Schweizer R. Transplantation of cadaver kidneys from pediatric and older donors. Transplantation Proceedings 1989, 21: 1938-9. PMID: 2652632.Peer-Reviewed Original Research
1988
Renal transplantation at Hartford Hospital: results of combined and flexible immunosuppression.
Schweizer R, Bow L, Roper L, Hull D, Bartus S. Renal transplantation at Hartford Hospital: results of combined and flexible immunosuppression. Clinical Transplants 1988, 147-58. PMID: 3154467.Peer-Reviewed Original ResearchConceptsLiving-related donor kidney transplantsDonor kidney transplantsCadaver kidney transplant recipientsKidney transplant recipientsGraft survivalKidney transplantOKT3 therapyTriple immunosuppressionTransplant recipientsHartford HospitalControl groupPretransplant blood transfusionsPrevious control groupSteroid-resistant rejectionUse of OKT3Year graft survivalMean serum creatinineEuro-Collins solutionAddition of CsAKidney transplantationRenal transplantationCMV infectionSerum creatinineBlood transfusionDR matching
1986
USE OF TWO DONOR-SPECIFIC TRANSFUSIONS FOR LIVING -RELATED DONOR KIDNEY TRANSPLANTATION
Schweizer R, Bartus S, Rovelli M, Bow L. USE OF TWO DONOR-SPECIFIC TRANSFUSIONS FOR LIVING -RELATED DONOR KIDNEY TRANSPLANTATION. Transplantation 1986, 42: 564-567. PMID: 3538543, DOI: 10.1097/00007890-198611000-00026.Peer-Reviewed Original Research
1985
EVIDENCE THAT CYCLOSPORINE-INCUBATED PLATELETS RETAIN FUNCTION AND RELEASE CYCLOSPORINE
Sharpe R, Schweizer R, Moore R, Calaluce R, Johnson R, Michalski P, Bow L. EVIDENCE THAT CYCLOSPORINE-INCUBATED PLATELETS RETAIN FUNCTION AND RELEASE CYCLOSPORINE. Transplantation 1985, 40: 102-105. PMID: 4012843, DOI: 10.1097/00007890-198507000-00021.Peer-Reviewed Original ResearchNeonatal tolerance increases efficacy of antisera production
Sharpe R, Schweizer R, Bow L. Neonatal tolerance increases efficacy of antisera production. Medical Hypotheses 1985, 17: 265-270. PMID: 3876502, DOI: 10.1016/0306-9877(85)90132-x.Peer-Reviewed Original Research
1982
Serologic considerations in donor-specific transfusion therapy for kidney transplantation.
Schweizer R, Bow L, Generas D, Bartus S. Serologic considerations in donor-specific transfusion therapy for kidney transplantation. Transplantation Proceedings 1982, 14: 374-7. PMID: 6810522.Peer-Reviewed Original Research